Among the pharma company updates, Teva’s new CEO Richard Francis is confident about the company’s growth, while Y-mAbs President Thomas Gad offered more insights into the company’s 35% workforce reduction and pipeline restructuring.

Under the deals, first announced in July, Israel-based Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. The final amounts of the settlements will depend on how many state and local governments opt into them.

Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of an expanding market.

Capping a tumultuous year of legal battles, Teva Pharmaceuticals has found a new president and CEO. Effective Jan. 1, 2023, Richard Francis will take the company’s reins as Kåre Schultz retires.

Teva Pharmaceuticals will pay up to $4.2 billion in the United States to settle claims related to its role in fueling the country’s opioid crisis, New York Attorney General Letitia James said on Thursday.

The European Commission informed Teva Pharmaceutical of its preliminary view that the company breached European Union (EU) antitrust rules with practices aimed at delaying competition to multiple sclerosis product Copaxone.

Teva Pharmaceutical Industries expects to finalize an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday, while confirming he was unlikely to renew his contract next year.

Teva Pharmaceutical Industries and AbbVie’s Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorney general Patrick Morrisey said on Wednesday.